journal article·2021-05-26Open access

Innate Immune Invisible Ultrasmall Gold Nanoparticles—Framework for Synthesis and Evaluation

Geyunjian Harry Zhu, Mohammad Azharuddin, Rakibul Islam, Hassan Rahmoune, Suryyani Deb, Upasona Kanji, Jyotirmoy Das, Johannes Osterrieth, Parminder Aulakh, Hashi Ibrahim-Hashi, Raghav Manchanda, Per H. Nilsson, Tom Eirik Mollnes, Maitreyee Bhattacharyya, Mohammad M. Islam, Jorma Hinkula, Nigel K. H. Slater, Hirak K. Patra

ACS Applied Materials & Interfaces· Volume 13· Issue 20

Abstract

Nanomedicine is seen as a potential central player in the delivery of personalized medicine. Biocompatibility issues of nanoparticles have largely been resolved over the past decade. Despite their tremendous progress, less than 1% of applied nanosystems can hit their intended target location, such as a solid tumor, and this remains an obstacle to their full ability and potential with a high translational value. Therefore, achieving immune-tolerable, blood-compatible, and biofriendly nanoparticles remains an unmet need. The translational success of nanoformulations from bench to bedside involves a thorough assessment of their design, compatibility beyond cytotoxicity such as immune toxicity, blood compatibility, and immune-mediated destruction/rejection/clearance profile. Here, we report a one-pot process-engineered synthesis of ultrasmall gold nanoparticles (uGNPs) suitable for better body and renal clearance delivery of their payloads. We have obtained uGNP sizes of as low as 3 nm and have engineered the synthesis to allow them to be accurately sized (almost nanometer by nanometer). The synthesized uGNPs are biocompatible and can easily be functionalized to carry drugs, peptides, antibodies, and other therapeutic molecules. We have performed in vitro cell viability assays, immunotoxicity assays, inflammatory cytokine analysis, a complement activation study, and blood coagulation studies with the uGNPs to confirm their safety. These can help to set up a long-term safety-benefit framework of experimentation to reveal whether any designed nanoparticles are immune-tolerable and can be used as payload carriers for next-generation vaccines, chemotherapeutic drugs, and theranostic agents with better body clearance ability and deep tissue penetration.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Gold and Silver Nanoparticles Synthesis and Applications · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.

Department of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden

Department of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway

Department of Biotechnology, Maulana Abul Kalam Azad University of Technology (MAKAUT), Kolkata 700064, India

Institute for Manufacturing (IfM), University of Cambridge, Cambridge CB3 0FS, U.K.

Linnaeus Center for Biomaterials Chemistry, Linnaeus University, Kalmar 391 82, Sweden

Research Laboratory, Nordland Hospital, Bodø, and Faculty of Health Sciences, K.G. Jebsen TREC, University of Tromsø, Tromsø 9037, Norway

Institute of Haematology and Transfusion Medicine, Calcutta Medical College, Calcutta 700073, India

Massachusetts Eye and Ear and Schepens Eye Research Institute, Dept of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States

Department of Surgical Biotechnology, University College London (UCL), London NW3 2PF, U.K.

Funding

Medical Research Council · Link?pings Universitet · British Council · H2020 Marie Sklodowska-Curie Actions · UK-India Education and Research Initiative

References (70)

Show source-provided references
1. 10.1038/nbt1006-121110.1038/nbt1006-1211 ↗
2. Gottipati A. · Drug Discov. World · 2012 · 13 · 81
3. 10.3390/jpm704001210.3390/jpm7040012 ↗
4. Galligan, F. Exploring Nanotechnology’s Daily Application https://axial.acs.org/2018/02/28/nanotechnology-daily-applications/ (Accessed April 13, 2020).
5. 10.1093/nsr/nww07310.1093/nsr/nww073 ↗
6. 10.1039/c9cc01741k10.1039/c9cc01741k ↗
7. 10.1155/2018/971283210.1155/2018/9712832 ↗
8. 10.1007/s11051-011-0583-910.1007/s11051-011-0583-9 ↗
9. 10.1166/asl.2011.316310.1166/asl.2011.3163 ↗
10. 10.1016/j.nano.2011.01.00710.1016/j.nano.2011.01.007 ↗
11. 10.1016/s2222-1808(12)60072-310.1016/s2222-1808(12)60072-3 ↗
12. 10.1166/jnn.2013.711310.1166/jnn.2013.7113 ↗
13. 10.2217/17435889.3.5.70310.2217/17435889.3.5.703 ↗
14. 10.1038/natrevmats.2017.1410.1038/natrevmats.2017.14 ↗
15. 10.1039/c4nr04569f10.1039/c4nr04569f ↗
16. 10.1039/c6sc03631g10.1039/c6sc03631g ↗
17. 10.1021/la051371210.1021/la0513712 ↗
18. 10.1002/smll.20090012610.1002/smll.200900126 ↗
19. 10.1007/s11051-009-9692-010.1007/s11051-009-9692-0 ↗
20. 10.1016/j.biomaterials.2005.01.01910.1016/j.biomaterials.2005.01.019 ↗
21. 10.2147/IJN.S5223610.2147/IJN.S52236 ↗
22. 10.1016/j.biomaterials.2010.10.02610.1016/j.biomaterials.2010.10.026 ↗
23. 10.1021/mp800032f10.1021/mp800032f ↗
24. 10.1002/elps.1150140121410.1002/elps.11501401214 ↗
25. 10.1016/j.nano.2008.08.00110.1016/j.nano.2008.08.001 ↗
26. Dobrovolskaia M. A. · 2016 · 1 · 1
27. 10.1016/j.nano.2011.10.00910.1016/j.nano.2011.10.009 ↗
28. 10.1007/s11095-012-0958-310.1007/s11095-012-0958-3 ↗
29. 10.1021/nn301282m10.1021/nn301282m ↗
30. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
31. 10.2147/ijn.s16545110.2147/ijn.s165451 ↗
32. 10.1073/pnas.162014511410.1073/pnas.1620145114 ↗
33. 10.1016/j.nano.2016.02.01910.1016/j.nano.2016.02.019 ↗
34. 10.2217/nnm.16.510.2217/nnm.16.5 ↗
35. 10.1016/j.biomaterials.2012.03.02010.1016/j.biomaterials.2012.03.020 ↗
36. 10.1039/c1cs15166e10.1039/c1cs15166e ↗
37. 10.1098/rstl.1857.001110.1098/rstl.1857.0011 ↗
38. 10.1039/df951110005510.1039/df9511100055 ↗
39. 10.3390/catal612018510.3390/catal6120185 ↗
40. 10.1007/s11051-010-9911-810.1007/s11051-010-9911-8 ↗
41. 10.1007/bf0195540510.1007/bf01955405 ↗
42. Slot J. W. · Eur. J. Cell Biol. · 1985 · 38 · 87
43. 10.1021/la201938u10.1021/la201938u ↗
44. 10.1021/acs.chemmater.5b0440610.1021/acs.chemmater.5b04406 ↗
45. 10.1021/la503209b10.1021/la503209b ↗
46. 10.1007/s13404-012-0069-210.1007/s13404-012-0069-2 ↗
47. 10.1021/jp201724210.1021/jp2017242 ↗
48. 10.1021/cm500316k10.1021/cm500316k ↗
49. 10.1016/j.aca.2009.07.01210.1016/j.aca.2009.07.012 ↗
50. 10.1016/j.ces.2018.06.04610.1016/j.ces.2018.06.046 ↗
51. 10.1021/jp305830p10.1021/jp305830p ↗
52. 10.1021/acs.chemmater.6b0179610.1021/acs.chemmater.6b01796 ↗
53. 10.1016/j.tips.2019.04.00210.1016/j.tips.2019.04.002 ↗
54. 10.1021/ar200260p10.1021/ar200260p ↗
55. 10.1016/j.nano.2007.03.00510.1016/j.nano.2007.03.005 ↗
56. 10.1002/smll.20040009310.1002/smll.200400093 ↗
57. 10.1002/smll.20070037810.1002/smll.200700378 ↗
58. 10.1016/j.cplett.2008.08.03910.1016/j.cplett.2008.08.039 ↗
59. 10.1021/bc049951i10.1021/bc049951i ↗
60. 10.1177/019262331142757210.1177/0192623311427572 ↗
61. 10.1007/s00441-010-1034-010.1007/s00441-010-1034-0 ↗
62. 10.1128/cdli.10.6.982-989.200310.1128/cdli.10.6.982-989.2003 ↗
63. 10.1002/(sici)1097-4636(19980305)39:3<478::aid-jbm19>3.0.co;2-610.1002/(sici)1097-4636(19980305)39:3<478::aid-jbm19>3.0.co;2-6 ↗
64. 10.1070/qe2010v040n12abeh01450710.1070/qe2010v040n12abeh014507 ↗
65. 10.1021/nn901118710.1021/nn9011187 ↗
66. 10.1117/1.jbo.17.10.10151210.1117/1.jbo.17.10.101512 ↗
67. Mollnes T. E. · Blood · 2002 · 100 · 1869
68. 10.1016/j.molimm.2013.05.22110.1016/j.molimm.2013.05.221 ↗
69. 10.18637/jss.v025.i0110.18637/jss.v025.i01 ↗
70. Kassambara A. · 2017 · 2